玻璃体切除联合地塞米松植入物治疗难治性黄斑水肿
回顾性分析62例患者(65眼)接受玻璃体切除联合玻璃体内地塞米松植入物治疗,比较糖尿病视网膜病变黄斑水肿(DME)、视网膜静脉阻塞(RVO)和非感染性后葡萄膜炎继发黄斑水肿的疗效。DME组最佳矫正视力从0.87改善至0.51,中央黄斑厚度从550.93μm降至338.10μm;RVO和葡萄膜炎组视力自第3个月起未再改善。DME组无水肿期最长(19.34±15.12个月),葡萄膜炎组降眼压药物使用最多(1.00±1.27)。
要点
- DME组视力和中央黄斑厚度改善最明显,无水肿期最长
- RVO和葡萄膜炎组视力自第3个月起未再改善
- 葡萄膜炎组眼压升高事件及降眼压药物使用最多
核心结论
- 玻璃体切除联合玻璃体内地塞米松植入物治疗DME、RVO和非感染性后葡萄膜炎黄斑水肿临床结局良好。
研究设计与样本
- 回顾性研究,纳入62例患者(29男33女,平均年龄51.19±14.41岁,共65眼),术后随访至1年。
主要发现
- DME组最佳矫正视力从0.87改善至0.51,RVO和葡萄膜炎组自第3个月起视力未再改善。
- 中央黄斑厚度各组均下降,DME组从550.93μm降至338.10μm。
- 无水肿期DME组最长(19.34±15.12个月),葡萄膜炎组12.91±7.85个月,RVO组8.50±8.76个月。
- 葡萄膜炎组降眼压药物使用(1.00±1.27)多于DME组(0.13±0.49)和RVO组(0.36±0.79)。
- 眼压升高事件最常见于术后第1周,尤其葡萄膜炎组。
临床怎么用
- 对DME、RVO及非感染性后葡萄膜炎继发难治性黄斑水肿,可考虑玻璃体切除联合地塞米松植入物。
- 术后第1周尤其是葡萄膜炎患者需密切监测眼压。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the efficacy of intraoperative intravitreal dexamethasone implant for macular edema secondary to diabetic retinopathy (DME), retinal vein occlusion (RVO), and noninfectious posterior uveitis. METHODS: A retrospective review of 62 patients (29 men and 33 women; mean age 51.19 ± 14.41 years; 65 eyes) was performed. Best-corrected visual acuity (in logarithm of the minimal angle of resolution), central foveal thickness, intraocular pressure, and postoperative edema-free period were postoperatively assessed up to 1 year. The preoperative and postoperative numbers of other intravitreal injections needed were compared. RESULTS: Best-corrected visual acuity gradually improved in the DME group (from 0.87 to 0.51) but failed to improve from Month 3 onward in the RVO and uveitis groups. Central foveal thickness decreased in all groups, especially in the DME group (from 550.93 to 338.10 μm). Edema-free period was longest in the DME group (19.34 ± 15.12 months), followed by the uveitis (12.91 ± 7.85 months) and RVO (8.50 ± 8.76 months) groups. Subjects in the uveitis group used more intraocular pressure-lowering agents (1.00 ± 1.27) than those in the DME (0.13 ± 0.49) and RVO (0.36 ± 0.79) groups. Increased intraocular pressure events were most frequent in postoperative Week 1, especially in the uveitis group. CONCLUSION: Vitrectomy combined with intravitreal dexamethasone implant for DME, RVO, and noninfectious posterior uveitis had a favorable clinical outcome.
引用
- Pang JP, Son G, Yoon YH, et al. COMBINED VITRECTOMY WITH INTRAVITREAL DEXAMETHASONE IMPLANT FOR REFRACTORY MACULAR EDEMA SECONDARY TO DIABETIC RETINOPATHY, RETINAL VEIN OCCLUSION, AND NONINFECTIOUS POSTERIOR UVEITIS. Retina. 2020. PMID: 30312262. doi:10.1097/IAE.0000000000002358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。